Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
06160 BEIGENE
RTNominal up91.950 +1.950 (+2.167%)
Others

21/01/2022 10:23

BeiGene (06160) gets sNDA accepted

[ET Net News Agency, 21 January 2022] BeiGene, Ltd. (06160) said the Center for Drug
Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted
a supplemental new drug application (sNDA) for BeiGene's BTK inhibitor BRUKINSA
(zanubrutinib) as a treatment for adult patients with Waldenstrom's macroglobulinemia
(WM).
BRUKINSA is a small molecule inhibitor of Bruton's tyrosine kinase (BTK) discovered by
BeiGene scientists that is currently being evaluated globally in a broad clinical program
as a monotherapy and in combination with other therapies to treat various B-cell
malignancies. (RC)

Back to Others

Remark: Real time quote last updated: 26/04/2024 16:45
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.